These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34688369)

  • 1. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
    Banerjee S; High J; Stirling S; Shepstone L; Swart AM; Telling T; Henderson C; Ballard C; Bentham P; Burns A; Farina N; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Tabet N
    Lancet; 2021 Oct; 398(10310):1487-1497. PubMed ID: 34688369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
    Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
    Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
    Banerjee S; Hellier J; Dewey M; Romeo R; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Knapp M; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
    Lancet; 2011 Jul; 378(9789):403-11. PubMed ID: 21764118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
    Banerjee S; Hellier J; Romeo R; Dewey M; Knapp M; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
    Health Technol Assess; 2013 Feb; 17(7):1-166. PubMed ID: 23438937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial.
    Henderson C; Knapp M; Stirling S; Shepstone L; High J; Ballard C; Bentham P; Burns A; Farina N; Fox C; Fountain J; Francis P; Howard R; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien JT; Price A; Swart AM; Tabet N; Telling T; Thomas AJ; Banerjee S
    Int Psychogeriatr; 2022 Oct; 34(10):905-917. PubMed ID: 35852256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
    Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
    PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of the Managing Agitation and Raising Quality of Life (MARQUE) intervention for agitation in people with dementia in care homes: a single-blind, cluster-randomised controlled trial.
    Livingston G; Barber J; Marston L; Stringer A; Panca M; Hunter R; Cooper C; Laybourne A; La Frenais F; Reeves S; Manela M; Lambe K; Banerjee S; Rapaport P
    Lancet Psychiatry; 2019 Apr; 6(4):293-304. PubMed ID: 30872010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
    Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
    Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.
    Higginson IJ; Brown ST; Oluyase AO; May P; Maddocks M; Costantini M; Bajwah S; Normand C; Bausewein C; Simon ST; Ryan K; Currow DC; Johnson MJ; Hart SP; Mather H; Krajnik M; Tanzi S; Ghirotto L; Bolton CE; Janowiak P; Turola E; Jolley CJ; Murden G; Wilcock A; Farsides B; Brown JM;
    Lancet Respir Med; 2024 Oct; 12(10):763-774. PubMed ID: 39265600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No benefit from mirtazapine for treating agitation in dementia.
    Drug Ther Bull; 2022 May; 60(5):68. PubMed ID: 35277387
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.
    Zhong KX; Tariot PN; Mintzer J; Minkwitz MC; Devine NA
    Curr Alzheimer Res; 2007 Feb; 4(1):81-93. PubMed ID: 17316169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa.
    Ballard CG; O'Brien JT; Reichelt K; Perry EK
    J Clin Psychiatry; 2002 Jul; 63(7):553-8. PubMed ID: 12143909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled trial of Lavender (Lavandula Angustifolia) and Lemon Balm (Melissa Officinalis) essential oils for the treatment of agitated behaviour in older people with and without dementia.
    Watson K; Hatcher D; Good A
    Complement Ther Med; 2019 Feb; 42():366-373. PubMed ID: 30670268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
    Meehan KM; Wang H; David SR; Nisivoccia JR; Jones B; Beasley CM; Feldman PD; Mintzer JE; Beckett LM; Breier A
    Neuropsychopharmacology; 2002 Apr; 26(4):494-504. PubMed ID: 11927174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.
    Romeo R; Knapp M; Hellier J; Dewey M; Ballard C; Baldwin R; Bentham P; Burns A; Fox C; Holmes C; Katona C; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Banerjee S
    Br J Psychiatry; 2013 Feb; 202():121-8. PubMed ID: 23258767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia.
    Meunier J; Creel K; Loubert A; Larsen KG; Aggarwal J; Hefting N; Oberdhan D
    Front Neurol; 2024; 15():1379062. PubMed ID: 39108660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil for the treatment of agitation in Alzheimer's disease.
    Howard RJ; Juszczak E; Ballard CG; Bentham P; Brown RG; Bullock R; Burns AS; Holmes C; Jacoby R; Johnson T; Knapp M; Lindesay J; O'Brien JT; Wilcock G; Katona C; Jones RW; DeCesare J; Rodger M;
    N Engl J Med; 2007 Oct; 357(14):1382-92. PubMed ID: 17914039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.